Welcome to our dedicated page for Viatris Ord Shs SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viatris Inc. (Nasdaq: VTRS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand how Viatris reports its financial performance, governance decisions and key corporate events as a global healthcare company that bridges generics and brands.
Viatris regularly files current reports on Form 8‑K to announce material events such as quarterly financial results, changes to bylaws, board appointments and other significant corporate actions. For example, the company has used Form 8‑K to report results for periods ended June 30 and September 30, 2025, and to disclose amendments to its bylaws related to proxy access and annual meeting timing. These filings often reference accompanying press releases that provide additional detail.
The company’s proxy statement on Schedule 14A (DEF 14A) offers insight into governance, board composition, executive compensation and strategic priorities. In its definitive proxy statement, Viatris discusses its enterprise-wide strategic review, capital return plans, pipeline progress and long-term shift toward a greater share of innovative brands, giving shareholders context for voting decisions and for evaluating management’s plans.
On this page, users can also monitor other SEC forms that may appear over time, such as annual and quarterly reports or any insider transaction reports on Form 4, as they become available. Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain technical language and help readers quickly identify topics such as revenue trends, strategic initiatives, bylaw changes and risk factors relevant to Viatris’ pharmaceutical preparation manufacturing business.
Filings are updated as they are released through EDGAR, allowing investors, analysts and other stakeholders to follow how Viatris communicates its financial condition, governance framework and strategic evolution through official regulatory channels.
Viatris Inc Chief Commercial Officer Corinne Le Goff reported equity compensation activity centered on restricted stock units and related tax withholding. On
Le Goff also received a new grant of 88,984 RSUs, each representing one future share of common stock. According to the vesting schedule, 29,662 of these RSUs are scheduled to vest on March 6, 2027, and 29,661 are scheduled to vest on each of March 6, 2028 and March 6, 2029, while 44,164 RSUs from the 2025 grant remain scheduled to vest on March 6, 2027 and March 6, 2028. Following these transactions, Le Goff directly holds 83,214 shares of Viatris common stock.
Viatris Inc Chief Financial Officer Theodora Mistras reported several equity-compensation transactions. On March 6, 2026, 41,711 restricted stock units (RSUs) granted on March 6, 2025 vested and were settled into common shares, along with 2,070.6039 related dividend equivalent units (DEUs).
To cover tax obligations on these vestings, 23,067 and 1,146 common shares were withheld at $14.16 per share, so there was no open‑market sale. She also received a new grant of 86,017 RSUs that convert one‑for‑one into Viatris common stock.
Following these transactions, Mistras directly held 70,645 common shares, plus 86,017 RSUs and 4,141 DEUs. The new RSU grant vests in three annual installments: 28,673 units on March 6, 2027 and 28,672 units on each of March 6, 2028 and March 6, 2029.
Maletta Matthew Joseph reported acquisition or exercise transactions in this Form 4 filing.
Viatris Inc reported that Chief Legal Officer Matthew Joseph Maletta received a grant of 59,323 restricted stock units on March 6, 2026. Each RSU represents one share of Viatris common stock. The award vests in three annual tranches: 19,775 RSUs on March 6, 2027 and 19,774 RSUs on each of March 6, 2028 and March 6, 2029. Following this compensation-related grant, Maletta holds 59,323 RSUs directly.
Viatris Inc director Michael Severino reported equity compensation-related transactions in company stock. On March 6, 2026, 25,112 restricted stock units and 918.455 dividend equivalent units vested and were converted into an equal number of Common Stock shares, leaving him with 26,031 common shares directly held after these acquisitions. The same day, he also received a new award of 15,890 restricted stock units, which are scheduled to vest on March 6, 2027. All activity reflects derivative exercises and grants at a price of $0.00 per unit under the Viatris Inc. 2020 Stock Incentive Plan, with no open-market purchases or sales disclosed.
Viatris Inc executive Andrew Enrietti reported routine equity compensation activity involving restricted stock units (RSUs), dividend equivalent units (DEUs) and related tax withholding. On
To cover tax liabilities from these vestings, 8,337 and 415 shares of common stock were withheld at
He also received a new award of 60,435 RSUs on March 6, 2026, each representing one share of common stock, scheduled to vest in three equal installments of 20,145 RSUs on March 6 of 2027, 2028 and 2029, in addition to remaining unvested RSUs and associated DEUs from the 2025 grant.
PARRISH MARK W reported acquisition or exercise transactions in this Form 4 filing.
Viatris Inc director Mark W. Parrish reported equity compensation activity involving restricted stock units and related common shares. Previously granted RSUs and dividend equivalent units vested into 24,834.4921 shares of common stock on March 6, 2026, and he received a new award of 15,890 RSUs that will vest on March 6, 2027. Following these transactions, he directly holds 165,230 shares of common stock and 15,890 unvested RSUs.
Viatris Inc director MARK RICHARD A reported compensation-related equity activity. On March 6, 2026, previously granted restricted stock units and related dividend equivalent units were exercised, delivering a total of about 24,834 shares of common stock as they vested in full.
The filing also shows a new award of 15,890 restricted stock units, each representing one future Viatris share, scheduled to vest on March 6, 2027. Following these transactions, the director directly holds 116,145 Viatris common shares. All visible derivative awards tied to this filing have now been converted into common stock.
Viatris Inc executive Paul Campbell reported equity compensation activity and related tax withholding in company stock. On
To cover tax liabilities on these vestings, 12,088 and 601 shares of common stock were withheld at
Viatris Inc Chief Executive Officer Scott Andrew Smith reported routine equity compensation activity. On March 6, 2026, 124,519 restricted stock units (RSUs) and 6,181.4237 dividend equivalent units (DEUs) were exercised into common stock, increasing his directly held share count to 1,329,326 shares.
To cover tax liabilities on these vestings, 48,999 and 2,433 shares of common stock were withheld at
Viatris Inc director Melina E. Higgins reported routine equity compensation activity. On March 6, 2026, she exercised restricted stock units and related dividend equivalent units into a total of 24,834.4921 shares of common stock, reflecting previously vested awards under the company’s stock incentive plan.
On the same date, she received a new grant of 15,890 restricted stock units that will vest on March 6, 2027. Following these transactions, she directly holds 146,048 shares of Viatris common stock and has an additional 74,000 shares reported as indirectly owned through her spouse. These entries are compensation-related acquisitions, not open-market purchases or sales.